12263 related articles for article (PubMed ID: 11668469)
21. Significance, specificity, and ultrastructural localization of HMB-45 antigen in pigmented ocular tumors.
Steuhl KP; Rohrbach JM; Knorr M; Thiel HJ
Ophthalmology; 1993 Feb; 100(2):208-15. PubMed ID: 8437829
[TBL] [Abstract][Full Text] [Related]
22. Microphthalmia transcription factor: a specific marker for malignant melanoma.
Vachtenheim J; Borovanský J
Prague Med Rep; 2004; 105(3):318-24. PubMed ID: 15782558
[TBL] [Abstract][Full Text] [Related]
23. The usefulness of tyrosinase in the immunohistochemical assessment of melanocytic lesions: a comparison of the novel T311 antibody (anti-tyrosinase) with S-100, HMB45, and A103 (anti-melan-A).
Clarkson KS; Sturdgess IC; Molyneux AJ
J Clin Pathol; 2001 Mar; 54(3):196-200. PubMed ID: 11253130
[TBL] [Abstract][Full Text] [Related]
24. Epithelial markers in malignant melanoma. A study of primary lesions and their metastases.
Ben-Izhak O; Stark P; Levy R; Bergman R; Lichtig C
Am J Dermatopathol; 1994 Jun; 16(3):241-6. PubMed ID: 7524376
[TBL] [Abstract][Full Text] [Related]
25. Comparison of HMB-45 monoclonal antibody and S-100 protein in the immunohistochemical diagnosis of melanoma.
Ordóñez NG; Ji XL; Hickey RC
Am J Clin Pathol; 1988 Oct; 90(4):385-90. PubMed ID: 2459952
[TBL] [Abstract][Full Text] [Related]
26. Acral lentiginous melanoma: an immunohistochemical study of 20 cases.
Kim YC; Lee MG; Choe SW; Lee MC; Chung HG; Cho SH
Int J Dermatol; 2003 Feb; 42(2):123-9. PubMed ID: 12709000
[TBL] [Abstract][Full Text] [Related]
27. Immunohistochemical diagnosis of malignant melanoma of the conjunctiva and uvea: comparison of the novel antibody against melan-A with S100 protein and HMB-45.
Heegaard S; Jensen OA; Prause JU
Melanoma Res; 2000 Aug; 10(4):350-4. PubMed ID: 10985669
[TBL] [Abstract][Full Text] [Related]
28. Comparison of immunohistochemical staining of the novel antibody melan-A with S100 protein and HMB-45 in malignant melanoma and melanoma variants.
Blessing K; Sanders DS; Grant JJ
Histopathology; 1998 Feb; 32(2):139-46. PubMed ID: 9543670
[TBL] [Abstract][Full Text] [Related]
29. Tyrosinase expression in malignant melanoma, desmoplastic melanoma, and peripheral nerve tumors.
Boyle JL; Haupt HM; Stern JB; Multhaupt HA
Arch Pathol Lab Med; 2002 Jul; 126(7):816-22. PubMed ID: 12088451
[TBL] [Abstract][Full Text] [Related]
30. Reliability of immunostaining using pan-melanoma cocktail, SOX10, and microphthalmia transcription factor in confirming a diagnosis of melanoma on fine-needle aspiration smears.
Clevenger J; Joseph C; Dawlett M; Guo M; Gong Y
Cancer Cytopathol; 2014 Oct; 122(10):779-85. PubMed ID: 24954720
[TBL] [Abstract][Full Text] [Related]
31. Immunohistochemical analysis of cutaneous malignant melanoma: comparison of S-100 protein, HMB-45 monoclonal antibody and NKI/C3 monoclonal antibody.
Fernando SS; Johnson S; Bäte J
Pathology; 1994 Jan; 26(1):16-9. PubMed ID: 8165017
[TBL] [Abstract][Full Text] [Related]
32. Micropthalmia transcription factor (MITF) as a diagnostic marker for metastatic melanomas negative for other melanoma markers.
Guo R; Franco-Palacios M; Russell M; Goddard L; Hassell L; Gillies E; Fung KM
Int J Clin Exp Pathol; 2013; 6(8):1658-64. PubMed ID: 23923085
[TBL] [Abstract][Full Text] [Related]
33. Melan-A: not a helpful marker in distinction between melanoma in situ on sun-damaged skin and pigmented actinic keratosis.
El Shabrawi-Caelen L; Kerl H; Cerroni L
Am J Dermatopathol; 2004 Oct; 26(5):364-6. PubMed ID: 15365366
[TBL] [Abstract][Full Text] [Related]
34. Quantitative comparison of MiTF, Melan-A, HMB-45 and Mel-5 in solar lentigines and melanoma in situ.
Kim J; Taube JM; McCalmont TH; Glusac EJ
J Cutan Pathol; 2011 Oct; 38(10):775-9. PubMed ID: 21797920
[TBL] [Abstract][Full Text] [Related]
35. [Reactivity of five different antibodies with benign and malignant melanocytic lesions].
Plótár V; Szentirmay Z; Orosz Z
Magy Onkol; 2008 Dec; 52(4):363-73. PubMed ID: 19068464
[TBL] [Abstract][Full Text] [Related]
36. [Distribution of melanoma-associated antigens (HMB 45 and S 100) in benign and malignant melanocytic tumors of the conjunctiva].
Steuhl KP; Rohrbach JM; Knorr M
Klin Monbl Augenheilkd; 1991 Sep; 199(3):187-91. PubMed ID: 1753671
[TBL] [Abstract][Full Text] [Related]
37. Microphthalmia transcription factor in malignant melanoma predicts occult sentinel lymph node metastases and survival.
Naffouje S; Naffouje R; Bhagwandin S; Salti GI
Melanoma Res; 2015 Dec; 25(6):496-502. PubMed ID: 26317170
[TBL] [Abstract][Full Text] [Related]
38. MITF accurately highlights epidermal melanocytes in atypical intraepidermal melanocytic proliferations.
Nybakken GE; Sargen M; Abraham R; Zhang PJ; Ming M; Xu X
Am J Dermatopathol; 2013 Feb; 35(1):25-9. PubMed ID: 22668579
[TBL] [Abstract][Full Text] [Related]
39. Recognition of malignant melanoma by monoclonal antibody HMB-45. An immunohistochemical study of 200 paraffin-embedded cutaneous tumors.
Wick MR; Swanson PE; Rocamora A
J Cutan Pathol; 1988 Aug; 15(4):201-7. PubMed ID: 3053811
[TBL] [Abstract][Full Text] [Related]
40. Melanoma biomarker expression in melanocytic tumor progression: a tissue microarray study.
Nazarian RM; Prieto VG; Elder DE; Duncan LM
J Cutan Pathol; 2010 Apr; 37 Suppl 1():41-7. PubMed ID: 20482674
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
